20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Shares of kidney dialysis provider Fresenius Medical Care AG & Co (NYSE:FMS) touched a 52-week low after the company cut its earnings outlook as costs surged and a U.S. staff shortage.
- The company flagged a decline in net income around a high teens percentage range and withdrew its 2025 targets.
- It also expects sales growth at the lower end of the previous forecast range.
- The company reported preliminary Q2 sales of €4.76 billion, +10% Y/Y but almost flat on constant currency.
- Operating income fell 20% to €341 million, while adjusted operating income was up 3% to €445 million.
- Adjusted Net income remained flat at €225 million.
- The company expects pressures from the U.S. labor market to persist in the year's second half.
- It said it no longer expected to achieve organic revenue growth in North American health care services this year.
- New CEO Carla Kriwet will start by October. Rice Powell will step down as CEO effective September 30.
- Price Action: FMS shares are down 14.3% at $19.28 during the market session on the last check Thursday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!